Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Costs of invasive meningococcal disease: a global systematic review|
|Citation:||PharmacoEconomics, 2018; 36(10):1201-1222|
|Bing Wang, Renee Santoreneos, Hossein Afzali, Lynne Giles, Helen Marshall|
|Abstract:||Background: Invasive meningococcal disease remains a public health concern because of its rapid onset and significant risk of death and long-term disability. New meningococcal serogroup B and combination serogroup ACWY vaccines are being considered for publicly funded immunization programs in many countries. Contemporary costing data associated with invasive meningococcal disease are required to inform cost-effectiveness analyses. Objective: The objective of this study was to estimate costs and resource utilization associated with acute infection and the long-term care of invasive meningococcal disease. Data Sources and Methods: PubMed, EMBASE, The Cochrane Library, health economic databases, and electronically available conference abstracts were searched. Studies reporting any costs associated with acute infection and long-term sequelae of invasive meningococcal disease in English were included. All costs were converted into purchasing power parity-adjusted estimates [international dollars (I$)] using the Campbell and Cochrane Economics Methods Group and the Evidence for Policy and Practice Information and Coordinating Centre cost converter. Results: Fourteen studies met our eligibility criteria and were included. The mean costs of acute admission ranged from I$1629 to I$50,796, with an incremental cost of I$16,378. The mean length of hospital stay was reported to be 6-18 days in multiple studies. The average costs reported for readmissions ranged from I$7905 to I$15,908. Key variables such as the presence of sequelae were associated with higher hospitalization costs and longer inpatient stay. No studies estimated direct non-healthcare costs and productivity loss. Ten studies reported only unadjusted mean values without using appropriate statistical methods for adjustment. Conclusions: Invasive meningococcal disease can result in substantial costs to healthcare systems. However, costing data on long-term follow-up and indirect costs used to populate health economic models are lacking.|
|Keywords:||Humans; Meningococcal Infections; Hospitalization; Length of Stay; Models, Economic; Cost-Benefit Analysis; Health Care Costs; Hospital Costs|
|Rights:||© Springer International Publishing AG, part of Springer Nature 2018|
|Appears in Collections:||Public Health publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.